Analysis Of Income And Expense [Abstract]

Xspray Pharma - Filing #679276

Concept	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue	—	—	– SEK	—	—	—	—	—	– SEK	—	—	—
Material income and expense [abstract]
Research and development expense	—	—	40 259 SEK	—	—	—	—	—	22 219 SEK	—	—	—
Finance income (cost)	—	—	2 049 SEK	—	—	—	—	—	1 403 SEK	—	—	—
Selling, general and administrative expense [abstract]
Selling, general and administrative expense	—	—	169 567 SEK	—	—	—	—	—	109 601 SEK	—	—	—
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations	—	—	184,000 SEK	—	—	—	—	—	– SEK	—	—	—
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	- SEK	- SEK	179 851 SEK	179 667 SEK	- SEK	184,000 SEK	– SEK	– SEK	131 670 SEK	131 670 SEK	- SEK	– SEK